{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:25Z","timestamp":1791765385168,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jvs.2024.08.032","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T04:59:47Z","timestamp":1724734787000},"page":"767-774.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cilostazol after endovascular therapy for femoropopliteal peripheral arterial disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"81","author":[{"given":"Christian D.","family":"Cerecedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-2636","authenticated-orcid":false,"given":"Aaron","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine S.","family":"Alia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"El Shazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro J.","family":"Candil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2024.08.032_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jvs.2024.08.032_bib2","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","article-title":"Surgery or endovascular therapy for chronic limb-threatening ischemia","volume":"387","author":"Farber","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1 SUPPL","key":"10.1016\/j.jvs.2024.08.032_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.107.735985","article-title":"Inhibition of restenosis in femoropopliteal arteries. Paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial","volume":"118","author":"Werk","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2024.08.032_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jvs.2012.12.066","article-title":"The United States study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the prot\u00e9g\u00e9 everflex nitinol stent system II (DURABILITY II)","volume":"58","author":"Matsumura","year":"2013","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1583\/13-4399MR.1","article-title":"Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions","volume":"21","author":"Armstrong","year":"2014","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2024.08.032_bib7","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/CIRCULATIONAHA.119.044697","article-title":"Mortality and paclitaxel-coated devices: an individual patient data meta-analysis","volume":"141","author":"Rocha-Singh","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2024.08.032_bib8","article-title":"Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jvs.2024.08.032_bib9","article-title":"Antiplatelet and anticoagulant drugs for prevention of restenosis\/reocclusion following peripheral endovascular treatment","volume":"2012","author":"Robertson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvs.2024.08.032_bib10","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jvs.2024.08.032_bib11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvs.2024.08.032_bib12","series-title":"Cilostazol (Pletal) FDA approval Letter","first-page":"1","author":"Temple","year":"1999"},{"key":"10.1016\/j.jvs.2024.08.032_bib13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jvs.2011.07.087","article-title":"Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells","volume":"55","author":"Takigawa","year":"2012","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/fcp.12195","article-title":"Cilostazol exerts antiplatelet and anti-inflammatory effects through AMPK activation and NF-kB inhibition on hypercholesterolemic rats","volume":"30","author":"da Motta","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jvs.2024.08.032_bib15","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib16","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib17","first-page":"1","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"The BMJ"},{"key":"10.1016\/j.jvs.2024.08.032_bib18","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2021"},{"key":"10.1016\/j.jvs.2024.08.032_bib19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jvs.2024.08.032_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4070\/kcj.2021.0246","article-title":"Clinical outcomes of atherectomy plus drug-coated balloon versus drug-coated balloon alone in the treatment of femoropopliteal artery disease","volume":"52","author":"Cha","year":"2022","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jvs.2024.08.032_bib21","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1253\/circj.CJ-18-0077","article-title":"Drug-coated balloon vs. conventional balloon angioplasty in dialysis patients with symptomatic femoropopliteal disease \u2014 A matched comparison","volume":"82","author":"Chou","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jvs.2024.08.032_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jcin.2014.10.016","article-title":"Outcomes of spot stenting versus long stenting after intentional subintimal approach for long chronic total occlusions of the femoropopliteal artery","volume":"8","author":"Hong","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2024.08.032_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.1003","article-title":"Retrospective multicenter registry for endovascular treatment with newer devices in over 25-cm femoropopliteal artery disease: a retrospective observational study","volume":"6","author":"Horie","year":"2023","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.jvs.2024.08.032_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1526602819860124","article-title":"Vessel calcification as a risk factor for in-stent restenosis in complex femoropopliteal lesions after Zilver PTX paclitaxel-coated stent placement","volume":"26","author":"Ichihashi","year":"2019","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2024.08.032_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1583\/11-3581.1","article-title":"Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis","volume":"18","author":"Iida","year":"2011","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2024.08.032_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/MDER.S21629","article-title":"A\u00a0better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine","volume":"4","author":"Ikushima","year":"2011","journal-title":"Med Dev Evid Res"},{"key":"10.1016\/j.jvs.2024.08.032_bib27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.2215\/CJN.05761207","article-title":"Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease","volume":"3","author":"Ishii","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jvs.2024.08.032_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clinthera.2010.01.007","article-title":"Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients","volume":"32","author":"Ishii","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jvs.2024.08.032_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1526602820950261","article-title":"Lumen Loss at 1 Year after bare nitinol stent implantation in the superficial femoral artery","volume":"28","author":"Ito","year":"2021","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2024.08.032_bib30","first-page":"790","article-title":"Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: observations from the retrospective multicenter analysis for femoropopliteal stenting (REAL-FP)","volume":"90","author":"Kamioka","year":"2017","journal-title":"Cathet Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2024.08.032_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/heartasia-2018-011114","article-title":"Antithrombotic therapy after femoropopliteal artery stenting: 12-month results from Japan postmarketing surveillance","volume":"11","author":"Kawarada","year":"2019","journal-title":"Heart Asia"},{"key":"10.1016\/j.jvs.2024.08.032_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejvs.2020.10.008","article-title":"Drug eluting stent vs. drug coated balloon for native femoropopliteal artery disease: a two centre experience","volume":"61","author":"Lee","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.avsg.2018.06.015","article-title":"Risk factors for restenosis after drug-coated balloon angioplasty for Complex femoropopliteal arterial occlusive disease","volume":"55","author":"Roh","year":"2019","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jvs.2010.03.050","article-title":"Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent","volume":"52","author":"Soga","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib35","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jvs.2011.06.024","article-title":"Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia","volume":"54","author":"Soga","year":"2011","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib36","first-page":"541","article-title":"Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol","volume":"79","author":"Soga","year":"2012","journal-title":"Cathet Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2024.08.032_bib37","article-title":"Vessel patency and associated factors of drug-coated balloon for femoropopliteal lesion","volume":"12","author":"Soga","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jvs.2024.08.032_bib38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1253\/circj.CJ-10-1029","article-title":"Long-term results of the S.M.A.R.T. ControlTM stent for superficial femoral artery lesions, J-SMART registry","volume":"75","author":"Suzuki","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.jvs.2024.08.032_bib39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/1526602817719284","article-title":"Impact of cilostazol administration on femoropopliteal in-stent restenosis","volume":"24","author":"Tomoi","year":"2017","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2024.08.032_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/2050312116660116","article-title":"Clinical impact and risk stratification of balloon angioplasty for femoropopliteal disease in nitinol stenting era: retrospective multicenter study using propensity score matching analysis","volume":"4","author":"Tsuchiya","year":"2016","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.jvs.2024.08.032_bib41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jvs.2008.02.062","article-title":"Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions","volume":"48","author":"Iida","year":"2008","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jacc.2008.09.020","article-title":"Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication","volume":"53","author":"Soga","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2024.08.032_bib43","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","article-title":"Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study","volume":"127","author":"Iida","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2024.08.032_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCINTERVENTIONS.118.006564","article-title":"Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery: the debate in SFA study","volume":"11","author":"Miura","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2024.08.032_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0270992","article-title":"Cilostazol effectiveness in reducing drug-coated stent restenosis in the superficial femoral artery: the ZERO study","volume":"17","author":"Miura","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jvs.2024.08.032_bib47","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1067\/mcp.2002.122474","article-title":"Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans","volume":"71","author":"Woo","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jvs.2024.08.032_bib48","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1253\/circj.71.1685","article-title":"Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting","volume":"71","author":"Min","year":"2007","journal-title":"Circ J"},{"issue":"2 SUPPL","key":"10.1016\/j.jvs.2024.08.032_bib49","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jvs.2024.08.032_bib50","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jvs.2013.11.096","article-title":"Cilostazol is associated with improved outcomes after peripheral endovascular interventions","volume":"59","author":"Warner","year":"2014","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib51","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0003319715604768","article-title":"Prevention of femoropopliteal in-stent restenosis with cilostazol","volume":"67","author":"Iftikhar","year":"2016","journal-title":"Angiology"},{"key":"10.1016\/j.jvs.2024.08.032_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1358863X19838327","article-title":"Outcomes with cilostazol after endovascular therapy of peripheral artery disease","volume":"24","author":"Megaly","year":"2019","journal-title":"Vasc Med"},{"key":"10.1016\/j.jvs.2024.08.032_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jvs.2020.08.125","article-title":"Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization","volume":"73","author":"Desai","year":"2021","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.08.032_bib54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13063-024-07935-y","article-title":"Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9\u2014pragmatic research and innovation through multinational experimentation","volume":"25","author":"Omerovic","year":"2024","journal-title":"Trials"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521424017865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521424017865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:30:42Z","timestamp":1779949842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521424017865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0741521424017865"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2024.08.032","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cilostazol after endovascular therapy for femoropopliteal peripheral arterial disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2024.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2024.07.109","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the Society for Vascular Surgery. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}